Viking Therapeutics Emerges as Top M&A Target: Oral VK2735 Phase 2 Data, Phase 3 VANQUISH Enrolled, $603M Cash Position

Viking Therapeutics (NASDAQ: VKTX, ~$3.6B market cap) is increasingly viewed as the most attractive independent obesity acquisition target in biotech, with Polymarket traders singling it out as the most likely takeout candidate in the sector.

The Asset: VK2735 (Dual GLP-1/GIP Agonist)

Viking controls both injectable and oral formulations of VK2735 — a rare situation for a small-cap biotech. Phase 2 data:

• Oral: Up to 12.2% mean weight loss at 13 weeks, with no plateau observed — weight loss was still accelerating at study end
• Injectable: Up to 14.7% weight loss at 13 weeks
• Phase 3 VANQUISH trials (injectable) are already fully enrolled
• Management expects to initiate Phase 3 oral trials later this year

Data presented at the European Congress on Obesity (ECO) in May 2026 showed higher oral doses drove "early, progressive weight loss without a plateau through Week 13" — suggesting efficacy might increase further with longer treatment.

"Viking Therapeutics increasingly looks like an acquisition candidate in biotech... large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available." — The Motley Fool (May 23, 2026)

Financial Position

• $603 million cash and investments at Q1 2026 end — cash runway into 2028
• Stock at ~$30/share; Wall Street analyst targets around $95/share if VK2735 continues producing competitive data
• No approved products, no meaningful revenue — pure pipeline bet

M&A Logic

For a larger pharma without a strong obesity franchise, acquiring Viking is far cheaper than waiting years while the asset appreciates toward commercialization. Pfizer, AstraZeneca, Roche, and Merck are all potential suitors. Viking's oral formulation is the differentiator — an oral dual GLP-1/GIP agonist would compete directly with orforglipron (mono-agonist) and oral Wegovy (mono-agonist), potentially with superior efficacy.

Investor implications: VKTX is a high-risk/high-reward M&A play. The Phase 3 data readouts will be the primary value catalysts; a takeout could happen before or after those readouts. Key risk: the obesity field is getting crowded fast, and if Phase 3 oral data disappoints, the acquisition premium could evaporate.